ArQule Wins FDA Approval to Begin Clinical Testing of ARQ 531 in B-cell Leukemias, Lymphomas
News
The U.S. Food and Drug Administration (FDA) has approved ArQule‘s Investigational New Drug (IND) application to begin clinical testing of the BTK inhibitor ARQ 531 in patients with B-cell malignancies. ... Read more